Aligos Therapeutics
(NASDAQ) ALGS
Aligos Therapeutics Financials at a Glance
Market Cap
$32.67M
Revenue (TTM)
$4.71M
Net Income (TTM)
-$90.32M
EPS (TTM)
-$8.70
P/E Ratio
-0.61
Dividend
$0.00
Beta (Volatility)
1.44 (Average)
Dividend
$0.00
Beta (Volatility)
1.44 (Average)
Price
$5.34
Volume
142
Open
$5.33
Price
$5.34
Volume
142
Open
$5.33
Previous Close
$5.34
Daily Range
$5.27 - $5.34
52-Week Range
$4.80 - $13.69
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.44 (Average)
Price
$5.34
Volume
142
Open
$5.33
Previous Close
$5.34
Daily Range
$5.27 - $5.34
52-Week Range
$4.80 - $13.69
Estimated Earnings Date
Aug 6, 2026
ALGS News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Aligos Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
82
CEO
Lawrence M. Blatt, PhD, MBA
Website
www.aligos.comHeadquarters
South San Francisco, CA 94080, US
ALGS Financials
Key Financial Metrics (TTM)
Gross Margin
89%
Operating Margin
-20%
Net Income Margin
-19%
Return on Equity
-122%
Return on Capital
-2%
Return on Assets
-1%
Earnings Yield
-1.64%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$32.67M
Shares Outstanding
6.19M
Volume
142
Avg. Volume
208.98K
Financials (TTM)
Gross Profit
$1.26M
Operating Income
-$87.99M
EBITDA
-$22.95M
Operating Cash Flow
-$82.50M
Capital Expenditure
-$437.00K
Free Cash Flow
-$82.94M
Cash & ST Invst.
$77.84M
Total Debt
$5.25M
Aligos Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$2.83M
+810.0%
Gross Profit
$2.83M
+810.0%
Gross Margin
100.00%
N/A
Market Cap
$32.67M
N/A
Market Cap/Employee
$466.77K
N/A
Employees
70
N/A
Net Income
-$23.04M
-153.5%
EBITDA
-$22.38M
-151.3%
Quarterly Fundamentals
Total Cash
$55.08M
-60.0%
Total Debt
$4.35M
-44.7%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$659.00K
-85.0%
Short Term Debt
$3.69M
+5.9%
Return on Assets
-1.40%
N/A
Return on Invested Capital
-2.32%
N/A
Free Cash Flow
-$23.20M
-10.7%
Operating Cash Flow
-$23.13M
-10.6%